Predilife S.A. (EPA:ALPRE)

Market Cap	2.96M -74.1%
Revenue (ttm)	835.81K +69.5%
Net Income	-3.93M
EPS	-1.00
Shares Out	3.95M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	761
Open	0.7520
Previous Close	0.8020
Day's Range	0.7500 - 0.7520
52-Week Range	0.7500 - 4.0000
Beta	0.24
Analysts	n/a
Price Target	n/a
Est. Earnings	Apr 23, 2027

About Predilife

Predilife S.A. designs and markets predictive tests for the occurrence of serious illnesses. It provides breast cancer predictive assessment; and multi-pathology predictive assessment. The company also offers MammoRisk, a breast cancer prediction test based on the patient’s individual risk; and DenSeeMammo, a breast density measurement software. Predilife S.A. was incorporated in 2004 and is headquartered in Villejuif, France.

• Industry: Diagnostics & Research
• Sector: Healthcare
• Founded: 2004
• Employees: 21
• Stock Exchange: Euronext Paris
• Ticker Symbol: ALPRE

Financial Performance

In 2025, Predilife's revenue was 835,809, an increase of 69.47% compared to the previous year's 493,202. Losses were -3.93 million, -7.74% less than in 2024.

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Nov 10, 2026

Data Sources Report a data error